



OPEN ACCESS

EDITED AND REVIEWED BY
Anastas Dimitrov Pashov,
Bulgarian Academy of Sciences (BAS),
Bulgaria

*CORRESPONDENCE

Catarina E. Hioe

✉ catarina.hioe@mssm.edu

✉ catarina.hioe@va.gov

RECEIVED 27 October 2023

ACCEPTED 02 November 2023

PUBLISHED 09 November 2023

CITATION

Hioe CE, Liu X, Banin AN, Heindel DW,
Klingler J, Rao PG, Luo CC, Jiang X,
Pandey S, Ordonez T, Barnette P,
Totrov M, Zhu J, Na´das A, Zolla-Pazner S,
Upadhyay C, Shen X, Kong X-P and
Hessell AJ (2023) Corrigendum:
Vaccination with immune complexes
modulates the elicitation of functional
antibodies against HIV-1.
Front. Immunol. 14:1329069.
doi: 10.3389/fimmu.2023.1329069

COPYRIGHT

© 2023 Hioe, Liu, Banin, Heindel, Klingler,
Rao, Luo, Jiang, Pandey, Ordonez, Barnette,
Totrov, Zhu, Na´das, Zolla-Pazner,
Upadhyay, Shen, Kong and Hessell. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1

Catarina E. Hioe^{1,2*}, Xiaomei Liu¹, Andrew N. Banin¹,
Daniel W. Heindel¹, Je´romine Klingler¹, Priyanka G. Rao¹,
Christina C. Luo³, Xunqing Jiang³, Shilpi Pandey⁴,
Tracy Ordonez⁴, Philip Barnette⁴, Maxim Totrov⁵, Jiang Zhu⁶,
Arthur Na´das⁷, Susan Zolla-Pazner¹, Chitra Upadhyay¹,
Xiaoying Shen⁸, Xiang-Peng Kong³ and Ann J. Hessell⁴

¹Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ²Research Service, James J. Peters VA Medical Center, Bronx, NY, United States, ³Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, United States, ⁴Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States, ⁵Molsoft L.L.C., San Diego, CA, United States, ⁶Department of Integrative Structural and Computational Biology and Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States, ⁷Department of Environment Medicine, New York University Grossman School of Medicine, New York, NY, United States, ⁸Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC, United States

KEYWORDS

HIV-1 vaccine, HIV-1 Env, antibody, immune complex (IC), virus neutralization, ADCP

A Corrigendum on

Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1

by Hioe CE, Liu X, Banin AN, Heindel DW, Klingler J, Rao PG, Luo CC, Jiang X, Pandey S, Ordonez T, Barnette P, Totrov M, Zhu J, Na´das A, Zolla-Pazner S, Upadhyay C, Shen X, Kong X-P and Hessell AJ (2023) Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1. *Front. Immunol.* 14:1271686. doi: 10.3389/fimmu.2023.1271686

In the published article, there was an error in **Figure 5** as published. MW965.26 was incorrectly listed as Clade B. It should be Clade C. The corrected **Figure 5** and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Group		Animal ID		ID50 in TZM-bl cells								
				SVA-MLV	TH023.6	MN.3	MW965.26	CM244.ec1	Ce1176_A3	962M651.1	Ce703010217_B6	246-F3_C10_2
				Ctrl	CRF01_AE Tier 1	Clade B Tier 1A	Clade C Tier 1A	CRF01_AE Tier 2	Clade C Tier 2	Clade C Tier 2	Clade C Tier 2	Clade AC Tier 2
1A	DNA/UFO-UC	661-5	54	66	42	134	32	70	52	51	64	
		662-5	<30	201	<20	32	<20	<30	33	<20	<20	
		664-5	80	108	168	496	283	147	223	229	335	
		665-5	86	42	67	200	45	109	65	121	129	
		666-5	<30	55	<20	30	<20	<30	<20	<20	<20	
		659-5	<30	68	<20	<20	<20	<30	<20	<20	<20	
1B	DNA/UFO-IC	660-5	80	302	75	147	33	96	47	67	100	
		663-5	<30	180	<20	<20	<20	<30	<20	<20	<20	
		667-5	<30	60	<20	<20	<20	<30	<20	<20	<20	
		668-5	<30	88	<20	<20	<20	<30	<20	<20	<20	
		673-6	<20	157	N/A	28	<20	<20	N/A	N/A	N/A	
		674-6	<20	<20	N/A	<20	<20	<20	N/A	N/A	N/A	
2A	DNA/V1V2-UC	677-6	<20	21	N/A	<20	<20	<20	N/A	N/A	N/A	
		678-6	<20	<20	N/A	26	<20	<20	N/A	N/A	N/A	
		683-6	21	<20	N/A	26	<20	<20	N/A	N/A	N/A	
		669-6	<20	21	N/A	<20	<20	<20	N/A	N/A	N/A	
		670-6	21	34	N/A	<20	<20	<20	N/A	N/A	N/A	
		671-6	26	21	N/A	25	<20	<20	N/A	N/A	N/A	
2B	DNA/V1V2-IC	672-6	<20	30	N/A	<20	<20	<20	N/A	N/A	N/A	
		684-6	24	31	N/A	24	<20	<20	N/A	N/A	N/A	
		Ctrl	CH01-31	N/A	0.264	0.755	3.030	0.055	N/A	5.217	0.092	0.175
		mAb	PG9	>33	N/A	N/A	N/A	N/A	0.015	N/A	N/A	N/A

FIGURE 5

Neutralization activities elicited in the four rabbit groups. Neutralization of HIV-1 pseudoviruses from different tiers and clades was tested in a standard assay using the TZM.bl target cells. Serum samples collected two weeks after the last immunization (week 14) were evaluated for neutralization activity. Virus pseudotyped with MLV was used as negative control, and control mAbs were also included for comparison. Bold values denote ID₅₀ titers measurable above cut-offs (above MLV control <30 or >3-fold higher than MLV control of >30).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.